{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-199857","form_type":"8-K","ticker":"PMVP","cik":"0001699382","company_name":"PMV Pharmaceuticals, Inc.","filed_at":"2025-09-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.705569+00:00","generated_at":"2026-05-17T07:02:03.594622+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"PMV Pharma reports 33% ORR for rezatapopt in TP53 Y220C tumors; NDA for ovarian cancer planned Q1 2027","bullets":["Overall ORR 33% (32/97 evaluable patients) across 8 tumor types; median duration of response 6.2 months.","Ovarian cancer cohort: 43% ORR (19/44), median DOR 7.6 months, includes one confirmed complete response.","Safety profile manageable: most TRAEs Grade 1-2, no discontinuations due to Grade 3 AST/ALT elevations, 3.7% discontinuation rate.","FDA feedback supports NDA for platinum resistant/refractory ovarian cancer; plan to enroll 20-25 more patients by Q1 2026.","NDA submission for rezatapopt in ovarian cancer targeted for end of Q1 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-199857","json":"https://secwatch.observer/filing/0001193125-25-199857.json","markdown":"https://secwatch.observer/filing/0001193125-25-199857.md","text":"https://secwatch.observer/filing/0001193125-25-199857.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1699382/000119312525199857/0001193125-25-199857-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1699382/000119312525199857/d90438d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T07:02:03.594622+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}